Astec LifeSciences (ASTEC) reports narrowed Q3 loss as CDMO momentum drives positive EBITDA

Astec LifeSciences Limited (BSE: 533138, NSE: ASTEC) reported a sharp sequential and year-on-year recovery in operational performance for Q3 FY26, driven by higher Enterprise volumes and stronger offtake in its Contract Development and Manufacturing Organization (CDMO) segment. While the company remained in net loss territory, improved margins led to a return to positive EBITDA at ₹4.8 crore, compared to a ₹3.8 crore loss in Q3 FY25.

The latest results mark a potential turning point in Astec LifeSciences’ ongoing restructuring efforts under the Godrej Agrovet Limited umbrella, signaling progress in cost containment and revenue normalization following steep losses in FY25. With consolidated revenue climbing 31 percent year-on-year to ₹125.5 crore, the company’s operational mix is beginning to tilt back toward higher-margin growth segments.

Why is Astec LifeSciences’ return to EBITDA-positive territory in Q3 FY26 strategically significant for the company’s recovery narrative?

After a prolonged phase of earnings volatility, Astec LifeSciences is showing early signs of stabilization in its financial trajectory. The Q3 FY26 topline of ₹125.5 crore represents not just a 31 percent jump over the same period last year, but also a 70 percent sequential increase over Q2 FY26, suggesting a material ramp-up in execution.

This growth was disproportionately driven by the CDMO and new products division, which contributed ₹77.6 crore to Q3 revenue—a nearly 30 percent year-on-year gain. While Enterprise sales also rose 36.7 percent to ₹46.6 crore, the scale of contribution from the CDMO segment hints at where Astec LifeSciences is finding commercial traction in a tough agrochemical market.

Chairman N B Godrej attributed the recovery to a combination of volume growth and enterprise margin improvement, noting that increased CDMO offtake was instrumental in driving profitability back into the black at the EBITDA level. This was reflected in a significant improvement in consolidated EBITDA, which flipped from a loss of ₹3.8 crore in Q3 FY25 to a profit of ₹4.8 crore in Q3 FY26.

However, net losses remain elevated at ₹15.7 crore for the quarter, albeit narrowed from ₹40.4 crore in Q3 FY25. These losses include exceptional items amounting to ₹2.1 crore, primarily stemming from labor code-related adjustments in gratuity and long-term compensated absences following new regulatory guidelines.

How are enterprise and CDMO segments performing in terms of revenue mix and geographical contribution?

Astec LifeSciences’ revenue mix for Q3 FY26 indicates a healthy dual-engine growth model with strong contributions from both Enterprise and CDMO segments. The Enterprise business generated ₹46.6 crore, up from ₹34.1 crore in the prior-year quarter, while the Contract Manufacturing and New Products vertical brought in ₹77.6 crore compared to ₹59.8 crore in Q3 FY25.

The geographic split also revealed strength in both domestic and export markets. Domestic revenues surged by 56 percent year-on-year to ₹37.9 crore, while export revenues rose 23.9 percent to ₹86.3 crore. This demonstrates a successful broad-based recovery that is not overly reliant on a single geography or product line.

For the nine-month period ended December 31, 2025, consolidated total income stood at ₹292 crore, up 9.5 percent from ₹266.6 crore in the same period last year. While this figure is more modest, the reduction in EBITDA losses from ₹66.9 crore to ₹11.2 crore over the same period indicates structural margin improvements beyond mere quarterly seasonality.

What are the underlying risks and operational priorities for Astec LifeSciences in the quarters ahead?

Despite the operational turnaround, Astec LifeSciences remains under pressure from continued net losses and regulatory uncertainty, particularly around India’s evolving labor law landscape. The ₹2.1 crore hit classified under exceptional items may be the first in a series of compliance-related adjustments, depending on how final rules evolve. This could introduce further volatility in upcoming quarters.

Operationally, the company must now demonstrate consistency in scaling both Enterprise and CDMO revenues while protecting margins. The Enterprise segment will need to sustain margin expansion despite commodity cost fluctuations and global agrochemical market headwinds. CDMO scalability, on the other hand, will depend on execution in formulation development, customer retention, and regulatory compliance across geographies.

Balance sheet health remains a latent concern, especially given accumulated losses totaling ₹73.1 crore over the first nine months of FY26. The company’s ability to stem cash burn and manage working capital cycles will determine whether this recovery extends into sustainable profitability.

How are institutional investors and markets likely to interpret Astec LifeSciences’ Q3 FY26 print?

The return to EBITDA profitability may serve as a confidence-restoring milestone for long-suffering investors, particularly those who saw the stock underperform across FY25 amid operational stress and bottom-line deterioration. However, any near-term rerating would likely be tempered by the persistence of net losses and the lack of explicit forward guidance.

With total income rising, margin discipline improving, and both domestic and export sales showing upward momentum, the tone from management was cautiously optimistic. Still, institutional investors may remain on the sidelines until the company demonstrates back-to-back quarterly consistency or articulates a clearer roadmap for full-year breakeven at the net profit level.

If CDMO volumes continue to ramp and Enterprise margins hold steady, FY27 could emerge as a critical inflection point. Until then, sentiment will likely remain tied to operational follow-through rather than narrative turnaround alone.

What are the key strategic and financial takeaways from Astec LifeSciences’ Q3 FY26 performance and how do they impact industry peers?

• Astec LifeSciences Limited reported Q3 FY26 revenue of ₹125.5 crore, up 31 percent year-on-year and 70 percent sequentially.
• EBITDA turned positive at ₹4.8 crore versus a loss of ₹3.8 crore in Q3 FY25, indicating margin recovery.
• Net loss narrowed to ₹15.7 crore from ₹40.4 crore in Q3 FY25, still reflecting structural challenges.
• CDMO and new products division contributed ₹77.6 crore, highlighting successful contract manufacturing scale-up.
• Enterprise revenue rose 36.7 percent year-on-year to ₹46.6 crore, with improved margins.
• Domestic revenues grew 55.9 percent, while exports rose 23.9 percent, showing balanced geographic traction.
• Exceptional items totaling ₹2.1 crore were driven by regulatory adjustments to labor codes.
• EBITDA loss for 9M FY26 reduced significantly to ₹11.2 crore from ₹66.9 crore in 9M FY25, underscoring operational leverage.
• Sustained margin improvement and CDMO scalability will be critical for long-term turnaround credibility.
• Investor sentiment likely to remain cautiously optimistic but contingent on earnings consistency.